Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI), an AI TechBio company and precision medicine pioneer, has scheduled its second quarter 2025 financial results announcement for August 12, 2025. The company will host a conference call and webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the results. A replay will be available on the company's Investor Relations website after the call.

News Market Reaction

-0.86%

1 alert

-0.86% News Effect

On the day this news was published, CAI declined 0.86%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences^® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025.

Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.

Conference Call Details:

Date: Tuesday, August 12, 2025
Time: 3:30 p.m. CT (4:30 p.m. ET)
Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967

A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.

About Caris Life Sciences 
Caris Life Sciences^® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

Investor Relations:
Narendra Chokshi
Senior Vice President, Corporate Development
nchokshi@carisls.com
917.689.3511

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-report-second-quarter-2025-financial-results-on-august-12-2025-302511341.html

SOURCE Caris Life Sciences

FAQ

When will Caris Life Sciences (CAI) report Q2 2025 earnings?

Caris Life Sciences will report its Q2 2025 earnings on Tuesday, August 12, 2025.

What time is the Caris Life Sciences (CAI) Q2 2025 earnings call?

The earnings conference call is scheduled for 3:30 p.m. CT (4:30 p.m. ET) on August 12, 2025.

How can I access Caris Life Sciences (CAI) Q2 2025 earnings call?

The earnings call can be accessed via live webcast at https://edge.media-server.com/mmc/p/hfsyg967.

Where can I find the replay of Caris Life Sciences (CAI) Q2 2025 earnings call?

A replay will be available on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com shortly after the call.